Patient characteristics
| Characteristic . | . |
|---|---|
| No. of patients | 79 |
| Median age at HCT, y (range) | 36 (2-57) |
| Patient sex, no. | |
| Female | 23 |
| Male | 56 |
| Donor sex, no. (%) | |
| Female | 28 (35) |
| Male | 51 (65) |
| Median WBC at diagnosis, × 109/L (range) | 26 (12-420) |
| History of CNS disease, no. (%) | |
| Yes | 13 (16) |
| No | 63 (80) |
| Unknown | 3 (4) |
| Radiation therapy before HCT, no. (%) | |
| Yes | 61 (77) |
| No | 13 (16) |
| Unknown | 5 (6) |
| Imatinib before HCT, no. (%) | |
| Yes | 17 (22) |
| No | 62 (78) |
| Disease status at HCT, no. (%) | |
| First complete remission | 49 (62) |
| Beyond CR1 | 30 (38) |
| Hematopoietic cell source, no. (%) | |
| Bone marrow | 43 (54) |
| Peripheral blood | 36 (46) |
| Conditioning regimen, no. (%) | |
| FTBI/VP16 | 67 (85) |
| FTBI/VP16/CY | 11 (14) |
| FTBI/VP16/BU | 1 (1) |
| GVHD prophylaxis, no. (%) | |
| CSA/MTX | 37 (47) |
| CSA/PSE | 23 (29) |
| CSA/PSE/MTX | 9 (11) |
| CSA/MMF | 4 (5) |
| TAC/SIROLIMUS | 3 (4) |
| CSA/MMF/MTX | 1 (1) |
| Unknown | 2 (3) |
| Characteristic . | . |
|---|---|
| No. of patients | 79 |
| Median age at HCT, y (range) | 36 (2-57) |
| Patient sex, no. | |
| Female | 23 |
| Male | 56 |
| Donor sex, no. (%) | |
| Female | 28 (35) |
| Male | 51 (65) |
| Median WBC at diagnosis, × 109/L (range) | 26 (12-420) |
| History of CNS disease, no. (%) | |
| Yes | 13 (16) |
| No | 63 (80) |
| Unknown | 3 (4) |
| Radiation therapy before HCT, no. (%) | |
| Yes | 61 (77) |
| No | 13 (16) |
| Unknown | 5 (6) |
| Imatinib before HCT, no. (%) | |
| Yes | 17 (22) |
| No | 62 (78) |
| Disease status at HCT, no. (%) | |
| First complete remission | 49 (62) |
| Beyond CR1 | 30 (38) |
| Hematopoietic cell source, no. (%) | |
| Bone marrow | 43 (54) |
| Peripheral blood | 36 (46) |
| Conditioning regimen, no. (%) | |
| FTBI/VP16 | 67 (85) |
| FTBI/VP16/CY | 11 (14) |
| FTBI/VP16/BU | 1 (1) |
| GVHD prophylaxis, no. (%) | |
| CSA/MTX | 37 (47) |
| CSA/PSE | 23 (29) |
| CSA/PSE/MTX | 9 (11) |
| CSA/MMF | 4 (5) |
| TAC/SIROLIMUS | 3 (4) |
| CSA/MMF/MTX | 1 (1) |
| Unknown | 2 (3) |
CNS indicates central nervous system; CY, cyclophosphamide; BU, busulfan; CSA, cyclosporin A; MTX, methotrexate; PSE, prednisone; MMF, mycophenolate mofetil; and TAC, tacrolimus.